Status:
COMPLETED
Telmisartan+HCTZ (Hydrochlorothiazide), Hypertension
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
This Post Marketing Surveillance (PMS) study aims to review the followings by investigating the actual practice of MicardisPlus Tablet on the market: 1. Unexpected adverse drug reactions (especially,...
Eligibility Criteria
Inclusion
- patients diagnosed with essential hypertension
Exclusion
- patients who took Micardis Plus before participating in this PMS study
Key Trial Info
Start Date :
September 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
6901 Patients enrolled
Trial Details
Trial ID
NCT00659607
Start Date
September 1 2003
Last Update
June 6 2014
Active Locations (326)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site 10
Busan, South Korea
2
Boehringer Ingelheim Investigational Site 11
Busan, South Korea
3
Boehringer Ingelheim Investigational Site 12
Busan, South Korea
4
Boehringer Ingelheim Investigational Site 13
Busan, South Korea